Top

01-21-2017 | Gastrointestinal disorders | Article

The Burdens, Concerns, and Quality of Life of Patients with Gastroparesis

Journal: Digestive Diseases and Sciences

Authors: Daohai Yu, Frederick V. Ramsey, William F. Norton, Nancy Norton, Susan Schneck, Tegan Gaetano, Henry P. Parkman

Publisher: Springer US

Abstract

Aims

The impact of gastroparesis on patients from the patient’s viewpoint is needed to better address treatment priorities. The aims of this study were to: (1) Delineate burdens and concerns of patients with gastroparesis; (2) investigate specific symptoms contributing to impaired quality of life (QOL) in gastroparesis.

Methods

The International Foundation for Functional GI Disorders gastroparesis survey questionnaire was developed to describe patients’ viewpoint about their experience with gastroparesis and included Patient Assessment of Upper GI Symptoms (PAGI-SYM) and SF-36 QOL survey.

Results

A total of 1423 adult patients with gastroparesis completed the survey. Average duration of gastroparesis symptoms was 9.3 years with time from onset to diagnosis 5.0 years. Patients felt that they receive good information regarding treatment options from physicians, the Internet, and Facebook. Patients rated their satisfaction with available treatment for their gastroparesis as dissatisfied (33%), somewhat dissatisfied (27%), neutral (14%), somewhat satisfied (15%), and satisfied (4%). Patients felt that gastroparesis symptoms that are most important to improve with treatment are nausea, stomach pain, and vomiting. Overall, there was a decreased quality of life by SF-36. Physical health QOL score was negatively correlated with symptoms including nausea (r = −0.37), upper abdominal pain (r = −0.37), and early satiety (r = −0.37).

Conclusions

This large series of patients with gastroparesis describes their burdens, concerns, and QOL. Nausea, vomiting, early satiety, and abdominal pain are important symptoms for treatment. Many patients are not satisfied with current treatments, wanting specific treatments for their disorder. Interestingly, a large number of patients find out about treatments, not only from their physician, but also using the Internet including social media.

Soykan I, Sivri B, Sarosiek I, Kiernan B, McCallum RW. Demography, clinical characteristics, psychological and abuse profiles, treatment, and long-term follow-up of patients with gastroparesis. Dig Dis Sci. 1998;43:2398–2404.CrossRefPubMed

Harrell SP, Studts JL, Dryden GW, Eversmann J, Cai L, Wo JM. A novel classification scheme for gastroparesis based on predominant-symptom presentation. J Clin Gastroenterol. 2008;42:455–459.CrossRefPubMed

Parkman HP, Yates K, Hasler WL, et al. Similarities and differences between diabetic and idiopathic gastroparesis. Clin Gastroenterol Hepatol. 2011;9:1056–1064.CrossRefPubMed

Pasricha PJ, Yates KP, Nguyen L, et al. Outcomes and factors associated with reduced symptoms in patients with gastroparesis. Gastroenterology. 2015;149:1762–1774.CrossRefPubMedPubMedCentral

Farup CE, Leidy NK, Murray M, Williams GR, Helbers L, Quigley EM. Effect of domperidone on the health-related quality of life of patients with symptoms of diabetic gastroparesis. Diabetes Care. 1998;21:1699–1706.CrossRefPubMed

DiBaise JK, Patel N, Noelting J, Dueck AC, Roarke M, Crowell MD. The relationship among gastroparetic symptoms, quality of life, and gastric emptying in patients referred for gastric emptying testing. Neurogastroenterol Motil. 2016;28:234–242.CrossRefPubMed

Rentz AM, Kahrilas P, Stanghellini V, et al. Development and psychometric evaluation of the patient assessment of upper gastrointestinal symptom severity index (PAGI-SYM) in patients with upper gastrointestinal disorders. Qual Life Res. 2004;13:1737–1744.CrossRefPubMed

Ware JE, Kosinski M, Dewey JE. How to score version 2 of the SF-36 ^® health survey. Lincoln, RI: QualityMetric Incorporated; 2000.

Drossman DA, Morris CB, Schneck S, et al. International survey of patients with IBS: symptom features and their severity, health status, treatments, and risk taking to achieve clinical benefit. J Clin Gastroenterol. 2009;43:541–550.CrossRefPubMedPubMedCentral

10.

Revicki DA, Rentz AM, Dubois D, et al. Development and validation of a patient-assessed gastroparesis symptom severity measure: the Gastroparesis Cardinal Symptom Index. Aliment Pharmacol Ther. 2003;18:141–150.CrossRefPubMed

11.

Ware JE, Kosinski M. SF-36 ^® physical and mental health summary scales: a manual for users of version 1. 2nd ed. Lincoln, RI: QualityMetric Inc; 2001.

12.

Hays RD, Morales LS. The RAND-36 measure of health-related quality of life. Ann Med. 2001;33:350–357.CrossRefPubMed

13.

Hays RD, Sherbourne CD, Spritzer KL, Dixon WJ. A microcomputer program (sf36.exe) that generates SAS Code for scoring the SF-36 health survey. In: Proceedings of the 22nd Annual SAS Users Group International Conference; 1996:1128–1132.

14.

Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 ^® health survey manual and interpretation guide. Boston, MA: New England Medical Center, The Health Institute; 1993.

15.

Revicki DA, Camilleri M, Kuo B, Szarka LA, McCormack J, Parkman HP. Evaluating symptom outcomes in gastroparesis clinical trials: validity and responsiveness of the Gastroparesis Cardinal Symptom Index-Daily Diary (GCSI-DD). Neurogastroenterol Motil. 2012;24:456–463.CrossRefPubMed

16.

Hui R. Gastroparesis: Clinical Evaluation of Drugs for Treatment: Guidance for Industry. Food and Drug Administration Center for Drug Evaluation and Research (CDER); 2015.

17.

Jung H, Choung RS, Locke GR III, et al. The incidence, prevalence, and outcomes of patients with gastroparesis, in Olmsted County, Minnesota, from 1996–2006. Gastroenterology. 2009;136:1225–1233.CrossRefPubMed

18.

Rey E, Choung RS, Schleck CD, Zinsmeister AR, Talley NJ, Locke GR III. Prevalence of hidden gastroparesis in the community: the gastroparesis “iceberg”. J Neurogastroenterol Motil. 2012;18:34–42.CrossRefPubMedPubMedCentral

19.

Choung RS, Locke GR III, Schleck CD, Zinsmeister AR, Melton LJ, Talley NJ. Risk of gastroparesis in subjects with type 1 and 2 diabetes in the general population. Am J Gastroenterol. 2012;107:82–88.CrossRefPubMed

20.

Jones KL, Russo A, Stevens JE, et al. Predictors of delayed gastric emptying in diabetes. Diabetes Care. 2001;24:1264–1269.CrossRefPubMed

21.

Hasler WL, Parkman HP, Wilson LA, et al. Psychological dysfunction is associated with symptom severity but not disease etiology or degree of gastric retention in patients with gastroparesis. Am J Gastroenterol. 2010;105:2357–2367.CrossRefPubMedPubMedCentral

22.

Jones KL, Russo A, Berry MK, et al. A longitudinal study of gastric emptying and upper gastrointestinal symptoms in patient with diabetes mellitus. Am J Med. 2002;113:449–455.CrossRefPubMed

23.

Chang J, Russo A, Bound M, et al. A 25-year longitudinal evaluation of gastric emptying in diabetes. Diabetes Care. 2012;35:2594–2596.CrossRefPubMedPubMedCentral

Be confident that your patient care is up to date

Medicine Matters is being incorporated into Springer Medicine, our new medical education platform.

Alongside the news coverage and expert commentary you have come to expect from Medicine Matters diabetes, Springer Medicine's complimentary membership also provides access to articles from renowned journals and a broad range of Continuing Medical Education programs. Create your free account »